Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93074Research ArticleVybor fiksirovannykh kombinatsiy lekarstvennykh sredstv v terapii khronicheskoy obstruktivnoy bolezni legkikhLeshchenkoI. V-BaranovaI. I-1503201012351128122021Copyright © 2010, Consilium Medicum2010[Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop repot Updated 2008. www. goldcopd.com Last accessed: June 2008.][Хроническая обструктивная болезнь легких. Под ред. А.Г.Чучалина. М.: Атмосфера, 2008.][Celli B, Zu Wallack R, Wang S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.][O\'Donnell D.E, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.][Tashkin D.P, Celli B, Senn S et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543–54.][Troosters T, Kesten S, Burkhart D et al. Effectiveness of Tiotropium as First Maintenance Drug in Patients with COPD. Secondary Analysis of the UPLIFT Trial. Am J Respir Crit Care Med 2009; 179: A2467.][Littner M.R, Llovite J.S, Tashkin D.P et al. Long - acting bronchodilatation with once - daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136–42.][Suissa S, Barnes P.J. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34 (1): 13–6.][Hubbard R.B, Smith C.J, Smeeth L et al. Inhaled corticosteroids and hip fracture: a population - based case - control study. Am J Respir Crit Care Med 2002; 166: 1563–6.][Suissa S, Baltzan M, Kremer R et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8.][Garbe E, Suissa S, Le Lorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–43.][Ernst P, Baltzan M, Deschenes J et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–74.][Gan W.Q, Man S.F, Sin D.D. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta - analysis. BMC Pulm Med 2005; 5: 3–10.][Hattotuwa K.L, Gizycki M.J, Ansari T.W et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double - blind, placebo - controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–6.][Bourbeau J, Christodoulopoulos P, Maltais F et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938–43.][Ito K, Ito M, Elliott W.M et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967–76.][Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol 2008; [Epub Ahead of Print PMD: 18817512].][Sin D.D, Man S.F.P, Marciniuk D.D et al.; for the ABC (Advair, Biomarkers in COPD) Investigators. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207–14.][Hartl D, Griese M. Surfactant protein D in human lung diseases. Eur J Clin Invest 2006; 36: 423–35.][Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74–81.][Calverley P.M, Anderson J.A, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 22: 356 (8): 775–89.][Полный список литературы приведен на сайте издательства]